A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Nemiralisib (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 05 Dec 2017 Planned End Date changed from 20 Feb 2019 to 25 Feb 2019.
- 05 Dec 2017 Planned primary completion date changed from 20 Feb 2019 to 25 Feb 2019.
- 05 Dec 2017 Status changed from not yet recruiting to recruiting.